340B Snapshot: Janssen's Discounts In US Program Have Risen 220% Over Past Five Years

Janssen's 2021 US price transparency report offers insights into why the company recently joined the growing number of major pharma manufacturers who are restricting 340B discounts to contract pharmacies participating in the program.

Lots Of Money Is Swirling Around Rx Drugs In The Supply Chain • Source: Alamy

Janssen Pharmaceuticals Inc.’s price concessions in the 340B outpatient drug discount program rose from $2bn in 2016 to $6.4bn in 2021, driven by the rapid growth in contract pharmacy participation in the program over the past five years, according to the company’s recently-released US Transparency Report for 2021.

From 2020 to 2021 alone, 340B discounts increased by more than $1bn, after reaching $5.3bn in 2020, Janssen reported. The...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Medicaid

PS-MarketAccess (Premium-2): Why Financial Scammers Are So Successful Targeting Doctors

 
• By 

Doctors are increasingly falling victim to financial scams due to their high incomes, busy schedules, and trust in professional networks. Recognizing the tactics scammers use and the reasons behind physicians’ susceptibility is essential for protecting medical professionals.

PBMs and Vertical Integration: CBO Adds To Growing Concerns About Negative Impacts

 

Congressional Budget Office responses to questions from US lawmakers on pharmacy benefit managers could add to the momentum for PBM reforms to go further than the current leading proposals.

Vertex Opens New Front In Patient Assistance Conflict Between Pharma, HHS Inspector General

 
• By 

Vertex’s fertility preservation assistance program would provide up to $70,000 in financial support for in vitro fertilization and other services to patients prescribed Casgevy.

CMS Proposal To Further Reduce Medicaid 'Best Prices' Thwarted, For Now

 
• By 

The agency says it will collect additional information from manufacturers on methods for adding up price concessions from the supply chain before moving ahead.

More from Government Payers

PBMs and Vertical Integration: CBO Adds To Growing Concerns About Negative Impacts

 

Congressional Budget Office responses to questions from US lawmakers on pharmacy benefit managers could add to the momentum for PBM reforms to go further than the current leading proposals.

Pink Sheet Podcast: What We Learned From The First Batch Of Medicare Negotiated Drug Prices

 

Pink Sheet reporter and editors discuss the take-aways from the landmark first Medicare negotiated drug prices and what additional information remains outstanding.

A Better Deal: Medicare Discounts Surpass Estimated PBM-Negotiated Rebates

 
• By 

But the amount of savings realized when the Medicare negotiated prices go into effect in 2026 remains the subject of debate.